Tyra Biosciences, Inc. (NasdaqGS: TYRA)
Health Care · Biotechnology · US
$19.60
-1.71% today · +38.9% 1Y
Tyra Biosciences, Inc. (NasdaqGS: TYRA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.37B and employs 87 people.
Over the last twelve months the share price has gained 38.9%, trading between 13.29 and 40.65.
Tweenvest scores Tyra Biosciences, Inc. across four factors: quality 40/100, value 56/100. Its strongest factor is value.
TYRA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.37B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.40
- Dividend yield
- —
- Beta (5Y)
- 0.75
- 52-week high
- $40.65
- 52-week low
- $13.29
- Avg volume (3M)
- —
- Shares outstanding
- 68.76M
- Employees
- 87
- Next earnings
- —
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
- ISIN
- US90240B1061
- Founded
- 2018
- Listed since
- Sep 15, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nektar TherapeuticsNasdaqCM: NKTR | $1.41B | $39.72 | -3.52% |
| Inhibrx Biosciences, Inc.NasdaqGS: INBX | $1.40B | $90.54 | -4.70% |
| Pacific Shuanglin Bio-pharmacy Co., Ltd.SZSE: 000403 | $1.39B | CN¥9.96 | -0.99% |
| AnaptysBio, Inc.NasdaqGS: ANAB | $1.37B | $46.08 | +0.28% |
| Chongqing Genrix Biopharmaceutical Co., Ltd.SHSE: 688443 | $1.37B | CN¥24.95 | -1.38% |
| Idorsia LtdSWX: IDIA | $1.36B | CHF4.20 | -5.83% |
| GenFleet Therapeutics (Shanghai) Inc.SEHK: 2595 | $1.35B | HK$28.60 | -10.46% |
| Pharma Mar, S.A.BME: PHM | $1.35B | €68.30 | -1.66% |
Figures last refreshed Oct 11, 2026.